Epidermal growth factor receptor targeted therapy by ZD 1839 (Iressa) in patients with brain metastases from non-small cell lung cancer (NSCLC)

Lung Cancer

Volumn 41, Issue 2, 2003, Pages 227-231

  Cappuzzo, Federico ^a   Ardizzoni, Andrea ^b   Soto Parra, Hector ^c   Gridelli, Cesare ^d   Maione, Paolo ^d   Tiseo, Marcello ^b   Calandri, Cesare ^a   Bartolini, Stefania ^a   Santoro, Armando ^c   Crinò, Lucio ^a  

^a BELLARIA HOSPITAL   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

^c HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^d S G MOSCATI HOSPITAL   (Italy)

Author keywords

Non small cell lung cancer; Thyrosine kinase inhibitor; ZD 1839

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB;

ADULT; AGED; ARTICLE; BRAIN; BRAIN METASTASIS; CANCER CHEMOTHERAPY; CASE REPORT; CLINICAL TRIAL; DISEASE COURSE; DRUG TARGETING; DRUG TOLERABILITY; FEMALE; HUMAN; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; MALE; PRIORITY JOURNAL; SKIN TOXICITY; TOXICITY; TREATMENT FAILURE;

EID: 0038166890     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-5002(03)00189-2     Document Type: Article

References (18)

1. Crino L., Scagliotti G.V., Ricci S., et al. Gemcitabine and cisplatin versus mitomycin, ifosfamide, and cisplatin in advanced non-small-cell lung cancer: a randomized phase III study of the Italian Lung Cancer Project. J. Clin. Oncol. 17:1999;3522-3530.
2. Wells A. Molecules in focus: EGF receptor. Int. J. Biochem. Cell Biol. 31:1999;637-643.
3. Kris M.G., Herbst R., Rischin D., et al. Objective regressions in non-small cell lung cancer patients treated in phase I trials of ZD1839 ('Iressa'), a selective tyrosine kinase inhibitor that blocks the epidermal growth factor receptor (EGFR). Lung Cancer. 29:(Suppl. 1):2000;72. poster 233.
4. Ciardiello F., Caputo R., Bianco R., et al. Antitumour effect and potentiation of cytotoxic drug activity in human cancer cells by ZD1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clin. Cancer Res. 6:2000;2053-2063.
5. Woodburn J.R., Barker A.J., Gibson K.H., et al. ZD1839, an epidermal growth factor tyrosine kinase inhibitor selected for clinical development. Proc. Am. Assoc. Cancer Res. 38:1997;633-634.
6. Fukuoka M., Yano S., Giaccone G., et al. Final results from a phase II trial of ZD 1839 (Iressa) for patients with advanced non-small cell lung cancer (IDEAL 1). Proc. Am. Soc. Clin. Oncol. 21:2002;298a. abstract 1188.
7. Kris M.G., Natale R.B., Herbst R.S., et al. A phase II trial of ZD 1839 (Iressa) in advanced non-small cell lung cancer (NSCLC) patients who had failed platinum- and docetaxel-based regimens (IDEAL 2). Proc. Am. Soc. Clin. Oncol. 21:2002;292a. abstract 1166.
8. Giaccone G., Johnson D.H., Manegold C., et al. A phase III clinical trial of ZD 1839 (Iressa) in combination with gemcitabine and cisplatin in chemotherapy-naive patients with advanced non-small-cell lung cancer (INTACT 1). Ann. Oncol. 13:2002;2. abstract 4o.
9. Johnson D.H., Herbst R., Giaccone G., et al. ZD 1839 (Iressa) in combination with paclitaxel and carboplatin in chemotherapy-naive patients with advanced non-small-cell lung cancer (NSCLC): results from a phase III clinical trial (INTACT 2). Ann. Oncol. 13:2002;127. abstract 468o.
10. Common toxicity criteria: National Institute of Health, Cancer Therapy Evaluation Program, Division of Cancer Treatment, Bethesda, 1993.
11. Therasse P. New guidelines to evaluate the response to treatment in solid tumors. J. Natl. Cancer Inst. 92:2000;205-216.
12. Shepherd F.A., Dancey J., Ramlau R., et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J. Clin. Oncol. 18:2000;2095-2103.
13. Perez-Soler R., Chachoua A., Huberman M., et al. A phase II trial of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor OSI-774, following platinum-based chemotherapy, in patients with advanced EGFR-expressing, non-small cell lung cancer (NSCLC). Proc. Am. Clin. Oncol. 20:2001;310a. abstract 1235.
14. Furuse K. IASLC Workshop, Progress and guidelines in the management of NSCLC, Bruges, September 8-12, 2002.
15. Saltz L., Rubin M., Hochster H., et al. Acne-like rash predicts response in patients treated with cetuximab (IMC-C225) plus irinotecan (CPT-11) in CPT-11 refractory colorectal cancer (CRC) that expresses epidermal growth factor receptor (EGFR). Clin. Cancer Res. 7:2001;3766S. abstract 559.
16. Cappuzzo F, Gregorc V, Benedetti G, et al. ZD 1839 (IRESSA) in heavily pretreated locally advanced or metastatic non-small-cell lung cancer (NSCLC): analysis of efficacy and correlation with HER2 and EGFR expression. Proceedings of American Society of Clinical Oncology and Molecular Therapeutics Symposium, San Diego November 8, 2002;10 (abstract 46).
17. Calvo B, Caskey L, Earp H. Real-time fluorescent quantitative PCR reveals increased HER2, HER3, and unchanged HER1 (EGFR) m RNA expression levels in colon carcinomas. Proceedings of 2001 American Association and Cancer Research International Conference 2002;7:3761s (abstract 536).
18. Heimberger A.B., Learn C.A., Archer G.E., et al. Brain tumors in mice are susceptible to blockade of epidermal growth factor receptor (EGFR) with the oral, specific, EGFR-tyrosine kinase inhibitor ZD1839 (Iressa). Clin. Cancer Res. 8:2002;3496-3502.